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Abstract—!The development of new technologies to monitor 
drugs concentration directly in patient’s blood is absolutely 
required to succeed in personalized drug therapies. In this 
study, Etoposide - a well-known anti-cancer drug - has been 
chosen as model for cyclic voltammetry detection of drugs. 
Carbon nanotubes are chosen as electron-transfer mediators to 
enhance the system sensitivity. A very low frequency and low 
slope triangular-wave potential is required to acquire cyclic 
voltammograms. Cyclic voltammograms are definitely needed 
for a correct identification and quantification of the drug 
concentration in the patient serum. The aim of the paper is to 
investigate the feasibility of VLSI fully-integration of cyclic 
voltammetry measurements as a tool to develop a low-cost chip 
for drug monitoring in personalized therapy. A triangular wave 
generator CMOS circuit is proposed by using Direct Digital 
Synthesis (DDS) method. The circuit is implemented in 0.18 μm 
technology and it presents the possibility of changing the slope of 
the triangular voltage in a wide range of 10 to 100mV/s.
Index Terms- anti-cancer drug, personalized therapy, carbon 
nanotube, cyclic voltammetry, low frequency, ramp-generator 
circuit.
I. INTRODUCTION 
In these last years it has been recognized that any drug 
therapy needs to be modified according to the individual 
patient, leading to the personalization of the pharmacological 
treatment. It has been reported [1] that the response rate of 
patients to drugs used in major diseases is typically in the 
range of 20% to 50%. There are many reasons why a patient 
might or might not respond to a drug or be affected by an 
adverse event. Among these are mis-dosing, drug–drug 
interactions, drug allergies and medication errors. However 
the main reason for inappropriate drug response has to be 
found in the genetic polymorphism of the proteins involved in 
drug metabolism. The present state-of-the-art technology 
offers some tools for monitoring the genetic predisposition to 
drug metabolism, but they only predict the response to the 
drug administration. Another tool is required to measure the 
drug concentration in the patient’s body during the 
pharmacological cure, which is not yet offered. These 
measurements are essential in the case of some 
pharmacological treatments based on drug regimens, such as
anti-cancer drug therapies [2].
Etoposide is a widely used anti-cancer drug, administered 
for the treatment of many kinds of tumours [3, 4]. In this 
work a Carbon NanoTube (CNT)-based biosensor for the 
direct monitoring of Etoposide has been proposed. The CNTs 
were used to obtain highly sensitive sensor [5]. The 
biosensing has carried out with the cyclic voltammetry, where 
the drug concentration is detected and quantified by 
measuring current peaks. Cyclic voltammetry is a well-
known technique that is widely used in various applications 
where electrochemical analysis is required. In order to 
measure the cyclic voltammogram of any drug, a very low 
frequency triangular voltage is applied between working and 
reference electrodes of the electrochemical cell and the 
current through working electrode is plotted versus the 
applied voltage using laboratory instruments. In recent 
applications in personalized therapy, which use implantable 
sensor to measure different drug and metabolism 
characteristics, the setup to generate the ramp voltage and 
read out the current has to be integrated on a single chip. 
Since the period of the ramp is very long (in the range of tens 
of seconds), it cannot be designed with usual methods. In this 
work, a technique to generate the appropriate ramp for cyclic 
voltammetry of a wide range of drugs is presented. In the 
current measurement side, some works have been done 
recently and been presented in [6].
In this paper cyclic voltammetry has been applied with 
different concentrations of Etoposide, and a circuit 
architecture to measure the cyclic voltammetry has been 
designed for integrate circuits development with 0.18μm
technology.
II. MATERIALS AND METHODS
A.  Materials
The electrodes were made of graphite working electrode 
(area, 12.56mm2), a graphite counter electrode and an 
Ag/AgCl reference electrode. The total area of the cell is 
22mm2. Carbon paste screen-printed electrodes  (model DRP-
110) and Multi walled carbon nanotubes (MWCNT) in 
powder (95% purity, with –COOH groups present at 5%) 
were purchased from Dropsens (Spain). The MWCNT
average diameter and length are 10nm and 1-2μm
respectively. MWCNT powder was diluted in Chloroform to 
The concentration of 1 mg/ml and then sonicated for 30 
minutes to obtain a homogeneous suspension with breaking
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Fig 2. Voltammogram acquired using a potential scan rate of 20 mV/sec,
during the detection of Etoposide (ETO) with MWCNTs Fig 1.  SEM of a central area of a graphite electrode with MWCNTs
macro-aggregates. Etoposide drug, purchased from Sigma in
powder, was firstly dissolved in DMSO (dimethyl sulfoxide), 
and then diluted in Phosphate Buffered Saline (PBS) with pH 
7.4 in aliquots of 5-10-20-30-40-50mM. A Philips/FEI XL-
30F microscope (with 2.5 nm resolution in UHR mode at 1 
kV) has been used to acquire Scanning Electron Microscopic 
(SEM) images. The high Hydrophobicity of the CNT-surface 
assures a quite good and stable in time electrical interface 
between the CNT and the electrodes. Then, the CMOS 
circuits under design will be connected to the screen-printed 
and nano-structured electrodes by means of commercially 
available interfaces for the embedded integration.
B. Electrode nanostructuration
30μl of MWCNT-chloroform solution was deposited onto 
the working electrode by drop casting: after having sonicated
the solution of MWCNTs and chloroform for 3-4s to break 
macro-aggregates, 2μl of the solution were drop cast each 
time until all 30μl of the solution was deposited. After the 
deposition, the chloroform evaporated and the nanotubes laid
down the electrode surface forming a 3D porous structure. 
Fig. 1 shows the acquired picture with SEM for CNTs drop 
casted onto the electrode surface. As it is shown in this 
picture, when carbon nanotubes are dropped onto the surface 
they form agglomerates of thin wrapped wires spread onto the 
surface.
C. Electrchemical measurements
The Etoposide detection was carried out by cyclic 
voltammetry under aerobic conditions. Voltammograms were 
acquired by using a Versastat 3 potentiostat (Princeton 
Applied Technologies). The electrode was covered with 100 
μl of PBS 100 mM (PBS 10X) at pH 7.4 to form the 
electrochemical cell. To obtain the voltammetric response to 
different drug concentrations, drops of drug solution with 
different concentration according to its pharmacological 
range (30-100 μM [7]), were added to the 100μl drop of PBS 
covering the electrode. The potential of the working electrode 
swept in the range of -600 to +600 mV vs Ag/AgCl with a 
scan rate of 20mV/sec. The peaks obtained in cyclic 
voltammetry were analyzed, and the values of current peaks 
at different drug concentrations were calculated using 
Gaussian approximation [8], to obtain the calibration curve.
III. EXPERIMENTAL RESULTS
The voltammetric response to different concentrations of 
Etoposide was measured. Results of these experiments are 
reported in Fig. 2 and 3. Fig. 2 reports the Etoposide 
detection as registered in cyclic voltammograms. It clearly 
shows that every single peak is growing up upon Etoposide 
concentration. The peak at around -200mV is due to the 
oxygen moieties derived from Carbon-nanotubes as has been 
already reported [9, 10]. Two oxidation peaks at +220mV and 
+450mV and a reduction peak at +150mV are clearly visible. 
Another reduction peak at +50mV is partially hidden by the 
peak at +150mV. These data confirm the peaks reported in 
[11] obtained through Etoposide cyclic voltammetry at glassy 
carbon electrode. The other reduction peak at +350mV is 
Drug Description Reduction 
potential 
Reference
Cyclo-
phosphamide
Erythromycin
Ifosfamide
Indinavir
Verapamil
Anticancer and 
immunosuppressive
Antibiotic
Anticancer and 
immunosuppressive
Anti-HIV
For Hypertension, 
angina pectoris, 
cardiac arrhythmia
-450mV
-625mV
-435mV
-750mV
-100mV
[12]
[13]
[12]
[14]
[15]
Table 1- Reduction potential (corresponds to the current peak) for 
different drugs using Cytochrome P450 3A4
Fig 3. Calibration curve obtained for Etoposide in the 
concentration range 30 μM -100 μM
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Fig 4. Electrochemical cell and a simplified potentiostat Fig 5. Capacitor charging/discharging method to generate the 
triangular voltage waveform 
Fig. 7 Three dimension 6 bit DAC [21]Fig. 6 DDS building blocks
probably due to the presence of secondary product that reacts
on the working electrode when the reduction potential is 
applied and needs more investigations. The calibration curve
worked out from the Gaussian approximation of the reduction 
peak at +220mV in the cyclic voltammograms is illustrated in
Fig. 3.
Detection limit and sensitivity are the parameters mostly
used to evaluate the measurement quality. The calibration 
curve has a sensitivity of 7.3uA μM-1 cm-2 (standard deviation 
of 0.65×10-4), and a detection limit of 0.046μM (calculated as 
three-times the signal-noise ratio [16]). The detection limit is 
well below the pharmacological range. The measured current 
has a linear dependency to the drug concentration, which is 
compatible with the electrochemical theory [17]. This 
demonstrates the possibility of detecting Etoposide in its 
pharmacological range with a completely acceptable 
sensitivity and detection limit.
The obtained cyclic voltammograms in Fig. 2 show a
13mV potential shift in current peak position from the lowest 
to the highest Etoposide concentration. The shifts in the peak 
with increasing the drug concentration, shows the necessity of 
using a potential sweep to draw all the peaks corresponding 
to different concentrations.
On the other hand, Cytochrome P450 can be used for the 
construction of P450-based biosensor [8, 12] to detect 
different drugs presence in the electrochemical cell at the 
same time, using the fact that different drugs have their 
reduction peaks in different potentials that can be used as the 
drug’s special fingerprint. So depending on what drugs are 
present in the solution, different peaks will appear in the 
cyclic voltammogram, Table 1 shows that reduction potential 
of some drugs detected by using Cytochrome P450 3A4 range 
from -100mV to -750mV, which corresponds to the peak 
position in the cell current. Thus, for detecting and correctly 
identifying different drugs within the electrochemical cell that 
is essential for multi- drug-detection, a linearly varying 
voltage needs to be applied to the electrochemical cell. 
IV. CIRCUIT DESIGN
Literature analysis of voltammetries with Etoposide and 
other drugs presented in [10] provided the following 
specifications for the circuit with three electrodes:
• To generate a triangular wave in amplitude range of    
-900 to +900mV and scan rate 10 to 100 mV/s. 
• To read the current flowing through the solution in the 
range -1000 to 1000 μA.
In this work, we propose a method to generate the desired 
triangular voltage to enable the cyclic voltammetry
measurement. To address the need for reading the current 
through the electrochemical cell, a circuit has been designed 
recently and presented in [6].
Fig. 4 shows a simplified electrochemical cell model with 
three electrodes together with two amplifiers acting as 
potentiostat and transimpedance amplifier. Potentiostat is 
used to apply and control the voltage between working and 
reference electrodes, and transimpedance amplifier is the 
most straightforward approach to convert the biosensor 
current into voltage for measurement purpose [18, 19].
A. Circuit specifications
To achieve the accurate voltammogram, the voltage 
between working and reference electrodes should change 
very slowly. If the voltage changes very rapidly, the 
biosensor current peak won't occur in the specific potential of 
the target molecule anymore. Therefore, it is not possible to 
distinguish among different targets. In the discussed case of 
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(a)
(b)
Fig. 8 Output voltage versus time, a) slope of the generated ramp is 
17mV/sec. b) different scan rates 8.6, 17, 66 &133 mV/sec 
(a)
(b)
Fig. 9 Zoom in to the output voltage with the scan rate of 17 mV/sec 
a) in the peak of the voltage b) in decreasing part
Etoposide the best slope for the ramp, which leads to a good 
response, is about 20 mV/sec and the voltage ranges from -
600mV to +600 mV. To be able to measure cyclic 
voltammogram of different drugs such as in [10] with this 
generated ramp, a voltage range of -900mV to +900mV and a 
scan rate range of 10 to 100 mV/s are considered.
B. Circuit architecture 
The conventional way to generate a ramp voltage is by 
charging and discharging a capacitor with a constant current 
source [20, 21, 22]. The resulting voltage across the capacitor 
is a ramp directly proportional with time,
Vout(t)= t × Ic/C (1)
 Fig. 5 shows the simplified circuit schematic of this 
method. Two comparators control the highest and lowest 
value of the triangular wave by turning off and on the current 
sources through the capacitor. In this circuit, the rising and 
falling slope of the generated ramp is directly proportional to 
the current sources value and inversely to the capacitor value. 
Assuming a maximum on chip capacitance about 100 pF, the 
required current to create this slope is few picoamperes. 
Current sources to generate this very low amount of current 
have not yet been achieved in any CMOS circuit, because it is 
in the range of MOS and capacitors leakage currents. So, 
providing an appropriate ramp potential that gives the correct 
peak is hardly possible by using analog design methods.
The method we are presenting here uses direct digital 
synthesizer (DDS) to generate a stepwise ramp voltage. It is a 
method to obtain timing signals from a clock source with 
programmable frequency. Generally a DDS waveform 
generator includes a numerically controlled oscillator and a
digital to analog converter (DAC). The former produces at its 
output a discrete-time, quantized version of the desired output 
waveform whose period is controlled by the digital word 
contained in the frequency-control-register (FCR). The 
sampled, digital waveform is converted to an analog 
waveform by the DAC. Fig. 6 shows the block diagram of 
DDS designed to generate the triangular waveform.
An addition/subtraction block is used to add/subtract the 
FCR to/from the accumulator in every clock pulse. The FCR 
value determines the slope of the ramp. The FCR size and 
also the add/sub number of bits are carefully designed to 
provide different scan rates with different ramp slopes in the 
desired range. We chose the clock frequency to be 5kHz and 
considering 4 steps in the given scan rate of 10 to 100 mV/s 
to cover the needs in different voltammetric measurements. 
Register lengths and add/sub sizes are 19 bits. Add/Sub block 
is realized using 19 full adders. 
The control unit is designed properly to generate the 
signals that are required for changing the operation from add 
to subtraction and vice versa, to provide the positive and 
negative slopes of the triangular wave. The last part of the 
circuit is the DAC. In this circuit the DAC will convert 
highest bits of the accumulator into analog waveform. The 
DAC accuracy is determined by the voltage resolution. In this 
application 9 MSB bits of accumulator are sufficient to yield 
the required resolution, which is 5mV in a full range of 1.8 V.
Low power consumption is essential for the circuits, which 
are for implantable applications. Thus, the R-string structure 
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for DAC is selected [23]. A 9-bit DAC is realized using 29
resistors (using undoped poly resistors). In this kind of DAC, 
analog multiplexers select the output voltage based on the 
digital input bits. In this work, three multiplexers are used, 
because according to [24] using three analog multiplexers to 
select the reference voltage leads to minimum number of 
logic gates for decoding the input signal and consequently 
lower delay, mismatch and area. Fig. 7 shows a three-
dimensional decoding scheme for a 6-bit DAC. 
V. SIMULATION RESULTS
The circuit is implemented in 0.18um CMOS technology. 
Digital blocks of the developed architecture are implemented 
in VHDL, while the DAC circuit has been designed in 
Cadence Virtuoso. To reduce the simulation time, an output 
strobe is used with a period equal to 12×10-6 times the 
generated ramp period. Fig. 8 shows the output voltage versus 
time for 8.6mV/sec, 17mV/sec, 66 mV/sec and 133mV/sec 
scan rates. Fig. 9 shows precisely the stepwise ramp for the 
scan rate of the 17 mV/sec over a short time period. The 
average power consumption of the analog part of the circuit 
(i.e. DAC) is 300nW, and the digital circuit consumes 
400nW.
VI. CONCLUSION
In this paper the possibility of detecting a drug by cyclic 
voltammetry has been investigated. Electrochemical 
acquisitions of cyclic voltammograms on CNT-electrodes in 
presence of different concentration of drug have been shown.
This study demonstrates the capability of cyclic voltammetry 
as a feasible technique for drug detection to implement in a 
biochip, for improving the biological recognition. 
A circuit schematic to generate a very low slope and low 
frequency ramp voltage to measure the cyclic voltammetry 
has been proposed based on the DDS method. The circuit has 
been designed to encompass more drugs detection using CV 
method in implantable applications and it is implemented in 
0.18um technology. The slope of the generated ramp voltage 
is controllable and varies from less than 10 mV/sec to more 
than 100 mV/sec with a rail-to-rail swing. The power 
consumption of the whole circuit consisting of both analog 
and digital parts is 700nW. The low power consumption 
makes this circuit also suitable for applications with fully 
implantable and remotely powered devices [25]. The 
presented circuit together with a current readout circuit will 
be fabricated on a chip to enable drug detection based on the 
CV method in a three-electrode biosensor cell. 
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